(Total Views: 322)
Posted On: 02/20/2020 2:30:28 PM
Post# of 149272
Check out this article. The title caught my eye "Antiviral Drug Market Worth 44.2 Billion by 2026, Rising Prevalence of HIV to Fuel Growth .
Insert-tag-here https://www.globenewswire.com/news-release/20...ights.html
"One of the most common forms of viral infection that is occurring across the world is HIV. The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data. The World Health Organization (WHO) stated that in the year 2018, approximately 37.9 million people were affected by HIV. However, around 770,000 people died of this disease. It proves that the rising cases of HIV is fueling the demand for specific and targeted treatment regimen."
Fortune Business Insights™ profiles some of the most prominent companies operating in the Antiviral Drugs Market. They are as follows:
Abbvie, Inc.
Novartis AG
Gilead Sciences
Mylan N.V.
GlaxoSmithKline
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Other key market players (INSERT CYTODYN HERE!!!!)
Insert-tag-here https://www.globenewswire.com/news-release/20...ights.html
"One of the most common forms of viral infection that is occurring across the world is HIV. The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data. The World Health Organization (WHO) stated that in the year 2018, approximately 37.9 million people were affected by HIV. However, around 770,000 people died of this disease. It proves that the rising cases of HIV is fueling the demand for specific and targeted treatment regimen."
Fortune Business Insights™ profiles some of the most prominent companies operating in the Antiviral Drugs Market. They are as follows:
Abbvie, Inc.
Novartis AG
Gilead Sciences
Mylan N.V.
GlaxoSmithKline
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Other key market players (INSERT CYTODYN HERE!!!!)
(0)
(0)Scroll down for more posts ▼
